Purdue Pharma (Canada) and BioDelivery Sciences International Inc. (BDSI) announce that BELBUCA (buprenorphine buccal soluble film) is now commercially available in Canada. This follows authorization from Health Canada for transfer of ownership of the Drug Identification Number (DIN) for BELBUCA to Purdue Pharma (Canada) in September 2017. BELBUCA (buprenorphine buccal soluble film) was authorized for sale in Canada on June 21, 2017 by Health Canada for the management of pain severe enough to require daily, continuous, long-term treatment and that is opioid-responsive and for which alternative options are inadequate. It is the first and only long-acting opioid that uses novel buccal film technology to deliver buprenorphine for appropriate patients living with chronic pain. Use of BELBUCA is not indicated in patients under 18 years of age.